辅助生殖技术与乳腺癌风险:基于人群的队列研究
中位随访约9年,ART组乳腺癌风险轻度升高(HR 1.14,95%CI 1.12-1.16),40岁及以上启动治疗者风险更高(HR 1.37,95%CI 1.29-1.45)。
要点
- ART治疗后乳腺癌风险较同龄未治疗人群轻度升高,HR 1.14。
- 40岁及以上启动ART治疗者乳腺癌风险进一步升高,HR 1.37。
- 40岁及以上首次分娩者中,ART治疗相关风险仍存在(HR 1.51)。
核心结论
- ART治疗后乳腺癌风险较年龄匹配的未治疗背景人群轻度升高,且启动治疗年龄≥40岁者风险进一步升高。
研究设计与样本
- 采用Cox回归分析,调整未产、教育水平、伴侣状态、年份、母亲乳腺癌史和年龄。
主要发现
- 随访中位9.69年(ART组)与9.28年(未治疗组),共5861例乳腺癌,ART组695例(1.1%)对未治疗组5166例(0.9%),P<0.0001。
- 调整后ART治疗女性乳腺癌风险轻度升高(HR 1.14,95%CI 1.12-1.16)。
- 所有不孕原因均与ART治疗后乳腺癌风险轻度相关。
- 启动ART治疗年龄越大乳腺癌风险越高,≥40岁启动者最高(HR 1.37,95%CI 1.29-1.45)。
- ≥40岁首次分娩女性中,ART治疗者乳腺癌风险仍升高(HR 1.51,95%CI 1.09-2.08)。
临床怎么用
- 对启动ART治疗女性,尤其≥40岁者,应告知乳腺癌风险轻度升高的信息并纳入个体化咨询。
- ART治疗前的乳腺健康评估与长期随访可按年龄风险分层考虑。
局限性
- 虽基于大型全国队列,仍需足够效能并充分调整混杂因素的研究,尤其在年龄代表性更广的队列中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is there an increased risk of breast cancer among women after ART treatment including ovarian hormone stimulation? SUMMARY ANSWER: The risk of breast cancer was slightly increased among women after ART treatment compared to age-matched, untreated women in the background population, and the risk was further increased among women initiating ART treatment when aged 40+ years. WHAT IS KNOWN ALREADY: The majority of breast cancer cases are sensitive to oestrogen, and ovarian hormone stimulation has been suggested to increase the risk of breast cancer by influencing endogenous oestrogen levels. Previous studies on ART treatment and breast cancer have varied in their findings, but several studies have small sample sizes or lack follow-up time and/or confounder adjustment. Recent childbirth, nulliparity and higher socio-economic status are breast cancer risk factors and the latter two are also associated with initiating ART treatment. STUDY DESIGN, SIZE, DURATION: The Danish National ART-Couple II (DANAC II) cohort includes women treated with ART at public and private fertility clinics in 1994-2016. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women with no cancer prior to ART treatment were included (n = 61 579). Women from the background population with similar age and no prior history of ART treatment were randomly selected as comparisons (n = 579 760). The baseline mean age was 33.1 years (range 18-46 years). Results are presented as hazard ratios (HRs) with corresponding CIs. MAIN RESULTS AND THE ROLE OF CHANCE: During follow-up (median 9.69 years among ART-treated and 9.28 years among untreated), 5861 women were diagnosed with breast cancer, 695 among ART-treated and 5166 among untreated women (1.1% versus 0.9%, P < 0.0001). Using Cox regression analyses adjusted for nulliparity, educational level, partnership status, year, maternal breast cancer and age, the risk of breast cancer was slightly increased among women treated with ART (HR 1.14, 95% CI 1.12-1.16). All causes of infertility were slightly associated with breast cancer risk after ART treatment. The risk of breast cancer increased with higher age at ART treatment initiation and was highest among women initiating treatment at age 40+ years (HR 1.37, 95% CI 1.29-1.45). When comparing women with a first birth at age 40+ years with or without ART treatment, the increased risk among women treated with ART persisted (HR 1.51, 95% CI 1.09-2.08). LIMITATIONS, REASONS FOR CAUTION: Although this study is based on a large, national cohort of women, more research with sufficient power and confounder adjustment is needed, particularly in cohorts with a broad age representation. WIDER IMPLICATIONS OF THE FINDINGS: An increased risk of breast cancer associated with a higher age at ART treatment initiation has been shown. Ovarian stimulation may increase the risk of breast cancer among women initiating ART treatment when aged 40+ years. Age-related vulnerability to hormone exposure or higher hormone doses during ART treatment may explain the increased risk. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by a PhD grant to D.V. from the Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Funding for establishing the DANAC II cohort was received from the Ebba Rosa Hansen Foundation. The authors report no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Vassard D, Pinborg A, Kamper-Jørgensen M, et al. Assisted reproductive technology treatment and risk of breast cancer: a population-based cohort study. Hum Reprod. 2021. PMID: 34580714. doi:10.1093/humrep/deab219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。